In response to these inspections, Foxconn has expressed its willingness to actively cooperate with relevant units involved in the investigation. They have further conveyed this message through a statement translated using online tools.
The news of this investigation has not gone unnoticed, as it has had an impact on both Foxconn and Apple. Foxconn's shares fell by 2.2% in Taiwan, while Apple's stock experienced a 0.9% decline in U.S. premarket trading.
Gou, who holds a 12.5% stake in Foxconn despite resigning from the company's board, has expressed his intentions to run for the Taiwanese presidency. His candidacy currently ranks fourth in the polls for the upcoming January election.
Sources close to Foxconn have suggested that the public revelation of this probe may be politically motivated, linked to the election and as a means of cautioning Foxconn regarding its plans to diversify production beyond China.
In conclusion, this investigation poses a significant challenge for Foxconn amidst the complex web of U.S.-China relations, global politics, and Taiwan's upcoming elections. The outcome of these investigations will undoubtedly have far-reaching implications for Foxconn's future endeavors.
Related Articles
![Costco Wholesale Announces Change in Leadership](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
Costco Wholesale Announces Change in Leadership
Costco Wholesale announces CEO succession plan with Ron Vachris taking over for Craig Jelinek, who will remain in advisory capacity until April. Despite a sligh...
![Roche to Acquire Carmot Therapeutics in $3.1 Billion Deal](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
Roche to Acquire Carmot Therapeutics in $3.1 Billion Deal
Roche announces its acquisition of Carmot Therapeutics for $3.1 billion, expanding their portfolio of obesity drugs. Positive market response seen. Categories:...
![FDA Orphan-Drug Designation for Rhenium Therapy in Breast Cancer Patients](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
FDA Orphan-Drug Designation for Rhenium Therapy in Breast Cancer Patients
Shares of Plus Therapeutics surge as FDA grants orphan-drug designation for rhenium therapy in breast cancer patients with leptomeningeal metastases. Urgent nee...